20 of the very best Amazon Canada deals we spotted this weekend — save up to 91% on tech, beauty and more
Dyson Purifier Hot+Cool HP07
Google Nest Doorbell (Wired, 2nd Gen)
Apple AirPods Pro 2 Wireless Earbuds
Portable Charger Power Bank
HOSHANHO Kitchen Knife in Japanese High Carbon Steel
NutriBullet PRO 900 Series Nutrient Extractor
Dyson Airstrait Straightener
Dr. Zitacne Patches for Face
Whether you're looking to restock your household essentials, upgrade your outdoor space or browse for some new skincare products, there are plenty of discounts to discover. Not sure where to start? Our trusty Canadian shopping experts have compiled this handy guide below.
Shop by category:
Home deals
Kitchen deals
Beauty deals
Fashion deals
Tech deals
Lawn & garden deals
In this guide:
Best Amazon weekend home deals 🏠 | Best Amazon weekend tech deals 🎧 | Best Amazon weekend kitchen deals ☕ | Best Amazon weekend beauty & wellness deals 🧴
Not in the Amazon mood? No worries:
Hate shorts or dresses? 11 pairs of breezy, loose-fitting pants you'll want to wear all summer — starting at $25
Lululemon just dropped 100s of summer sale styles — 13 of the best finds under $100
There are more than 3,300 items on sale at Anthropologie right now — and they're all an extra 40% off
Best Amazon weekend home deals
Save 26%: Dyson Purifier Hot+Cool HP07 for $665 (was $900)
88% off: YKYI Electric Spin Scrubber for $50 (was $400)
Snag 76% off: High Pressure 10-Mode Handheld Shower for $34 (was $139)
Dyson Purifier Hot+Cool HP07
Take 72% off: Robot Vacuum and Mop Combo for $190 (was $670)
Score 38% off: Google Nest Doorbell (Wired, 2nd Gen) for $150 (was $240)
Google Nest Doorbell (Wired, 2nd Gen)
Best Amazon weekend tech deals
Save 25%: Apple AirPods Pro 2 Wireless Earbuds for $247 (was $329)
59% off: 16-inch jumper Laptop for $330 (was $800)
Snag 68% off: iPhone Charger 3pack 10FT Long Lightning Cable for $13 (was $40)
Apple AirPods Pro 2 Wireless Earbuds
Take 82% off: Monster N-Lite 203 AirLinks Wireless Earbuds for $26 (was $146)
Score 91% off: Portable Charger Power Bank for $27 (was $300)
Portable Charger Power Bank
Best Amazon weekend kitchen deals
Save 52%: HOSHANHO Kitchen Knife for $38 (was $80)
20% off: KitchenAid Artisan Series 5 Quart Tilt-Head Stand Mixer for $380 (was $475)
Snag 62% off: Fully Automatic Food Saver Vacuum Sealer for $38 (was $100)
HOSHANHO Kitchen Knife in Japanese High Carbon Steel
Take 43% off: NutriBullet PRO 900 Series Nutrient Extractor for $63 (was $110)
Score 34% off: Philips 2000 Series Airfryer - 4.4 qt for $66 (was $100)
NutriBullet PRO 900 Series Nutrient Extractor
Best Amazon weekend beauty & wellness deals
Save 45%: Ion Hair Dryer AC Motor 1800 W Hair Dryer for $38 (was $70)
14% off: Dyson Airstrait Straightener for $600 (was $700)
Snag 46% off: IPL Hair Removal Device for $70 (was $130)
Dyson Airstrait Straightener
Take 42% off: Dr. Zitacne Patches for Face for $14 (was $24)
Score 20% off: Dreamegg Sunrise Sound Machine Alarm Clock for $80 (was $100)
Dr. Zitacne Patches for Face
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Thermo Fisher shares climb as Q2 top and bottom line exceed estimates
-- Thermo Fisher Scientific Inc (NYSE:TMO) reported second-quarter earnings that topped expectations, with revenue also coming in ahead of forecasts. The company reported adjusted EPS of $5.36, beating the analyst estimate of $5.23. Revenue rose 3% from a year earlier to $10.85 billion, above the $10.68 billion consensus. Shares in the medical equipment maker were up 2.3% in premarket trading Wednesday as of 06:06 ET. 'Our exceptional team continues to execute at a high level, enabling customer success while navigating the macroenvironment," said Marc N. Casper, chairman, president, and CEO of Thermo Fisher Scientific. Adjusted operating income reached $2.38 billion, slightly up from $2.35 billion in the same period last year. Adjusted operating margin slipped to 21.9% from 22.3% a year ago. Related articles Thermo Fisher shares climb as Q2 top and bottom line exceed estimates These Under-the-Radar Stocks Offer Better Risk-Reward Ratio Than Nvidia If Powell goes, does Fed trust go with him?
Yahoo
12 minutes ago
- Yahoo
Wolverine Worldwide Announces Second Quarter Fiscal 2025 Conference Call for August 6, 2025
ROCKFORD, Mich., July 23, 2025--(BUSINESS WIRE)--Wolverine World Wide, Inc. (NYSE: WWW) today announced that it expects to report its second quarter fiscal 2025 financial results on Wednesday, August 6, 2025, at approximately 6:30 a.m. ET. Following the press release, the Company will host a conference call at 8:30 a.m. ET to review results and discuss current business trends. Investors and analysts interested in joining the call are invited to dial 1-800-715-9871 (international callers, please dial 1-646-307-1963) approximately five minutes prior to the start of the call. The conference call will be broadcast live and accessible under "Webcasts & Presentations" in the Investor Relations section of A recorded replay of the call will be available shortly after the conclusion of the call and remain available until August 13, 2025. To access the telephone replay, dial 1-800-770-2030 (international callers, please dial 1-609-800-9909). The access code for the replay is 9927992. ABOUT WOLVERINE WORLDWIDE Founded in 1883, Wolverine World Wide, Inc. (NYSE:WWW) is one of the world's leading designers, marketers, and licensors of branded casual footwear and apparel, performance outdoor and athletic footwear and apparel, kids' footwear, industrial work boots and apparel, and uniform footwear. The Company's portfolio includes Merrell®, Saucony®, Sweaty Betty®, Hush Puppies®, Wolverine®, Chaco®, Bates®, HYTEST®, and Stride Rite®. Wolverine Worldwide is also the global footwear licensee of the popular brands Cat® and Harley-Davidson®. Based in Rockford, Michigan, for more than 140 years, the Company's products are carried by leading retailers in the U.S. and globally in approximately 170 countries and territories. Wolverine Worldwide is a Great Place to Work® Certified™ company. For additional information, please visit our website, View source version on Contacts Jared Filippone, CFA (616) 894-8576 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12 minutes ago
- Yahoo
BD Announces First Pharma-Sponsored Clinical Trial Using BD Libertas™ Wearable Injector Technology for Biologic Drugs
FRANKLIN LAKES, N.J., July 23, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announces the first pharma-sponsored combination product clinical trial using the BD Libertas™ Wearable Injector for subcutaneous delivery of complex biologics. The selection of BD Libertas™ Wearable Injector for this pharma-sponsored trial follows successful outcomes from more than 50 BD-conducted pre-clinical and clinical studies, including a device clinical study demonstrating excellent performance with 100% of study participants stating they would likely use the BD Libertas™ Wearable Injector if prescribedi,ii. The pharma-sponsored combination product clinical trial represents a significant advancement in accelerating innovation in drug-device combination products that provide greater flexibility for patients, including potential conversion from infused medications that require patients to travel to a hospital or clinic to more convenient patient care in various settings, including self-injection at home. "This trial demonstrates BD's commitment to helping pharma companies by advancing large-volume injection science, ensuring therapies are accessible and patient friendly by offering more efficient and convenient options for biologics," said Patrick Jeukenne, worldwide president of BD Pharmaceutical Systems. "BD's enhanced testing capabilities acquired through ZebraSci and the proven capabilities of the BD Libertas™ Wearable Injector technology further position BD as an innovative leader in drug delivery." The BD Libertas™ Wearable Injector is an innovative, prefilled, patient ready-to-use drug delivery systemiii designed to enable delivery of complex biologics via subcutaneous injection. The biologics market is expected to grow to more than $670 billioniv by 2030 and for pharmaceutical companies developing these complex drugs, the BD Libertas™ Wearable Injector offers a customizable, patient-centric solution. The BD Libertas™ Wearable Injector: Supports delivery of high-viscosity biologics (up to 50 centipoise), enabling a wide range of subcutaneous therapies Is offered in 2 to 5 mL and 5 to 10 mL configurations providing flexibility for diverse therapeutic requirements Features a fully mechanical, patient ready-to-use design with a simple "peel, stick and click" mechanism, requiring no end-user filling or assemblyiii BD's ongoing validations of fill-finish and final assembly processes with multiple Contract Manufacturing Organizations (CMOs) enable the company to support pharmaceutical partners from development through commercial-scale production. For more information about how BD Libertas™ Wearable Injector is enabling biologic therapy delivery, visit About BD Libertas™ Wearable InjectorBD Libertas™ Wearable Injector is a product in development; some statements are forward looking and are subject to a variety of risks and uncertainties. BD Libertas™ Wearable Injector is a device component intended for drug-device combination products and not subject to FDA 510(k) clearance or separate EU CE mark certification. About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit or connect with us on LinkedIn at X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. Contacts: Media: Investors: Fallon McLoughlin Adam Reiffe BD Corporate Communications BD Investor Relations 201.258.0361 201.847.6927 i Early feasibility clinical study of investigational BD Libertas™ Wearable Injector (WI) evaluated 5ml, non- Newtonian ~8cP subcutaneous placebo injections in 52 healthy adult subjects for functionality, tissue effects, subject tolerability (100mm Visual Analog Scale (VAS)) and acceptability (questionnaires with 5-point Likert or yes /no responses). Tissue effects were measured from WI removal post-injection through 24 hours with calipers (wheals) or graded on a 5-point scale (erythema, bleeding) from 0-none to 4-severe, significant, respectively. Where tissue effects were observed, the majority (>50%) were resolved within 60 minutes and all within 24 hours. Subject pain (100mm VAS) peaked mid-injection (mean 9.1mm, SD 13.4) and rapidly resolved within 30 minutes (mean 0 .4mm, SD 2.6). Subjects found acceptable (Likert agree + strongly agree or yes responses) their peak pain (≥90.2%), injection site appearance (≥92.2% ).ii Woodley, W. D. et al. Clinical Evaluation of an Investigational 5ml Wearable Injector in Healthy Human Subjects. Clin Transl Sci. 2021 May;14(3):859-869. Pharma filled and assemblediv Mordor Intelligence (2025). Biologics Market Size - Industry Report on Share, Growth Trends & Forecasts Analysis (2025 - 2030). View original content to download multimedia: SOURCE BD (Becton, Dickinson and Company) Sign in to access your portfolio
